Get the Stockscreener App
15.97
0.13%
0.02
After Hours:
15.94
-0.03
-0.19%
Castle Biosciences Inc stock is traded at $15.97, with a volume of 441.00K.
It is up +0.13% in the last 24 hours and down -19.55% over the past month.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
See More
Previous Close:
$15.95
Open:
$15.93
24h Volume:
441.00K
Relative Volume:
0.98
Market Cap:
$461.05M
Revenue:
$219.79M
Net Income/Loss:
$-57.47M
P/E Ratio:
-7.4279
EPS:
-2.15
Net Cash Flow:
$-19.25M
1W Performance:
-0.81%
1M Performance:
-19.55%
6M Performance:
-47.26%
1Y Performance:
-34.04%
1-Day Range:
$15.62
$16.06
1-Week Range:
$15.45
$16.43
52-Week Range:
$15.45
$35.84
Castle Biosciences Inc Stock (CSTL) Company Profile
Name
Castle Biosciences Inc
Sector
Industry
Phone
866-788-9007
Address
505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX
Compare CSTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
15.97 | 464.84M | 219.79M | -57.47M | -19.25M | -2.15 |
|
TMO
Thermo Fisher Scientific Inc
|
402.82 | 148.60B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.90 | 132.07B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
513.36 | 40.34B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
111.92 | 30.82B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
140.33 | 23.70B | 15.50B | 1.33B | 2.16B | 7.34 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Apr-30-21 | Initiated | Lake Street | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Dec-27-19 | Reiterated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | BTIG Research | Buy |
| Aug-19-19 | Initiated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | Robert W. Baird | Outperform |
| Aug-19-19 | Initiated | SVB Leerink | Outperform |
View All
Castle Biosciences Inc Stock (CSTL) Latest News
Castle Biosciences, Inc. (CSTL) Unveils Largest Real-World Melanoma Risk Study at ASCO 2025 - Yahoo Finance
Castle Biosciences Presents Innovative Research on Melanoma Risk Stratification at ASCO 2025 - Nasdaq
New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's - GlobeNewswire
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Consensus Rating of “Buy” by Brokerages - Defense World
Man Group plc Buys Shares of 13,302 Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Nuveen Asset Management LLC Has $12.41 Million Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Deutsche Bank AG Buys 7,495 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Bank of America Corp DE Raises Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences amends charter, stockholders vote By Investing.com - Investing.com India
Castle Biosciences Holds Annual Stockholders Meeting - TipRanks
Castle Biosciences amends charter, stockholders vote - Investing.com
Some Confidence Is Lacking In Castle Biosciences, Inc. (NASDAQ:CSTL) As Shares Slide 28% - simplywall.st
Castle Biosciences stock hits 52-week low at $15.66 - Investing.com Australia
Castle Biosciences stock hits 52-week low at $15.66 By Investing.com - Investing.com South Africa
Scotiabank Issues Pessimistic Forecast for Castle Biosciences (NASDAQ:CSTL) Stock Price - Defense World
Castle Biosciences (CSTL) Target Price Updated by Scotiabank | C - GuruFocus
Castle Biosciences (CSTL) Target Price Updated by Scotiabank | CSTL Stock News - GuruFocus
Castle Biosciences (CSTL) Price Target Revised by Scotiabank | C - GuruFocus
Castle Biosciences to Present at the 2025 Jefferies Global Healt - GuruFocus
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference | CSTL Stock News - GuruFocus
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times
Castle Biosciences Executive Team Reveals Strategic Updates at Jefferies Healthcare Conference - Stock Titan
90,563 Shares in Castle Biosciences, Inc. (NASDAQ:CSTL) Purchased by D. E. Shaw & Co. Inc. - Defense World
Ameriprise Financial Inc. Has $8.42 Million Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Northern Trust Corp Boosts Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Jane Street Group LLC Reduces Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Voya Investment Management LLC Sells 668 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Price T Rowe Associates Inc. MD Purchases 1,837 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences confirms UM test’s efficacy - Investing.com
Castle Biosciences confirms UM test’s efficacy By Investing.com - Investing.com India
Castle Biosciences (CSTL) Presents New Data on Uveal Melanoma Ri - GuruFocus
Castle Biosciences to buy Previse - MSN
Castle Biosciences (CSTL) Presents New Data on Uveal Melanoma Risk Prediction | CSTL Stock News - GuruFocus
Castle Biosciences Reports Independent Validation of DecisionDx-UM Test with PRAME Gene Expression Data at ARVO 2025 - Nasdaq
Real-World Study Confirms Long-Term Performance of - GlobeNewswire
Texas public company to acquire Baltimore cancer diagnostic firm - The Business Journals
Castle Biosciences projects $287-$297M revenue for 2025 amid strategic acquisitions and growth initiatives - MSN
Canaccord Genuity Group Has Lowered Expectations for Castle Biosciences (NASDAQ:CSTL) Stock Price - Defense World
Castle Biosciences, Inc. (NASDAQ:CSTL) Q1 2025 Earnings Call Transcript - Insider Monkey
Castle Biosciences (CSTL) Champions Skin Cancer Awareness Initiatives | CSTL Stock News - GuruFocus
Castle Biosciences Celebrates Skin Cancer Awareness Month - The Manila Times
Castle Biosciences Partners with Melanoma Organizations to Promote Skin Cancer Awareness and Education in May - Nasdaq
Castle Biosciences (CSTL) Rating Maintained as Price Target Lowe - GuruFocus
Castle Biosciences (CSTL) Rating Maintained as Price Target Lowered | CSTL Stock News - GuruFocus
Castle Biosciences (CSTL) Reports Strong Q1 2025 Revenue Growth - GuruFocus
Castle Biosciences (CSTL) Target Price Reduced Despite Strong Re - GuruFocus
Nike To $70? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Castle Biosciences (CSTL) Target Price Reduced Despite Strong Revenue Report | CSTL Stock News - GuruFocus
Castle Biosciences (CSTL) Receives Price Target Adjustment by Ca - GuruFocus
Canaccord Adjusts Price Target for Castle Biosciences (CSTL) | C - GuruFocus
Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Castle Biosciences Inc Stock (CSTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
1.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):